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Clinical and Procedural Characteristics
Case # Age Sex Coronary Dominance Hemodynamic support Access Guide Wire Anticoagulation Antiplatelet
Ejection
Fraction Total Fluoroscopy Time Total Contrast Volume
1 43 M Right-dominant with patent
stents
No Femoral 7F-EBU 3.75 BMW Bivalirudin Aspirin þ Prasugrel 58% 45.9 min 450 mL
2 71 M Right-dominant with patent
vessel
No Femoral 6F-EBU 4.5 BMW Bivalirudin Aspirin þ Clopidogrel 50% 23.6 min 225 mL
3 80 M Right-dominant with patent
vessel
No Radial 7F-EBU 3.5 (sheath less) BMW Heparin Aspirin þ Ticagrelor 68% 18.9 min 165 mL
4 68 W Right-dominant; 100%
occlusion
Impella 2.5 LVAD Femoral 7F-EBU 3.75 BMW/Wiggle Heparin Aspirin þ Ticagrelor 62% 32.6 min 220 mL
5 70 M Right-dominant; patent RCA
stents
IABP Femoral 7F-EBU 3.5 BMW Bivalirudin ASA þ Clopidogrel 63% 13.1 min 135 mL
6 83 W Right-dominant; 90% prox
RCA
Impella CP Femoral 7F-EBU 3.5 BMW Bivalirudin ASA þ Ticagrelor 27% 26.7 min 250 mL
Angiographic Details of Left Main Lesion and Outcomes
Case # LM Pre-Intervention Stenosis LM Lesion Length LM Stent Implanted
LM Post-Intervention
Stenosis
Non-LM PCI (Total Vessels
Treated) Total # of Stents implanted Clinical Procedural Success Technical Success
Periprocedural
Complications
1 90% 25 mm Promus 3.5x20 0% Prox & mid LAD, diagonal
branch (3)
4 Yes Yes None
2 70% 8 mm Promus 4.0x12 0% None (1) 1 Yes Yes None
3 70% 15 mm Promus 4.0x16 0% Prox LAD (2) 2 Yes Yes Right forearm hematoma
4 80% 28 mm Promus 4.0x32 0% Mid LAD, LCX (2) 1 Yes Yes CK-MB 22.2
5 70% 34 mm Promus 2.75x38 mm 0% Prox LAD, LCX (2) 1 Yes Yes None
6 LM equivalent (90% ostial
LCX& 70% ostial LAD)
20 mm LAD, 12 mm LCX Xience 3.0x23 mm in LAD &
Xience 3.0x15 mm in LCX
0% LAD, LCX, and RCA (3) 3 Yes Yes None
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this study was to demonstrate the feasibility of robotic PCI for un-
protected left main stenosis.
METHODS The robotic CorPath 200 robotic system (Corindus Vascular
Robotics, Waltham, MA) consists of a robotic arm mounted on the
cardiac catheterization table that consists of a drive housing a single-
use sterile cassette, which is connected to the guiding catheter. While
sitting in the non-sterile, radiation-shielded cockpit, the operator
remotely controls delivery and removal of intracoronary devices
including the guidewire, angioplasty balloons, and stents. The data-
base for the ongoing PRECISION registry was queried at a single center
to identify all unprotected left main robotic PCI procedures performed
and outcomes are reported.
RESULTS During the study period 102 robotic PCI procedures were
performed our center of which 6 were identiﬁed as unprotected left
main stenosis (age 6914 years; 67% male). All 6 subjects underwent
successful PCI (ﬂuoroscopy time 26.811.4 min, with an average of 1.8
stents and 2.2 vessels treated/patient). Clinical and procedural success
was 100%. Three of the 6 subjects underwent robotic left main PCI
without hemodynamic support while 2 were supported with percu-
taneous left ventricular hemodynamic assistance using the Impella 2.5
device (Abiomed, Danvers, MA) and 1 with intra-aortic balloon pump.
CONCLUSIONS This is the ﬁrst report demonstrating the feasibility of
robotic PCI for unprotected left main stenosis. Left main disease was
treated robotically in the absence and presence of adjunctive hemo-
dynamic support. Though this report demonstrates the feasibility of
performing robotic PCI in a high-risk cohort of patients, further
studies are needed to examine the safety and effectiveness of this
approach in a larger sample of patients.
CATEGORIES CORONARY: Complex and Higher Risk Procedures for
Indicated Patients (CHIP)
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BACKGROUND Rotational atherectomy (RA) is recommended by
current guidelines as a provisional (bailout) procedure for heavily
calciﬁed or severely ﬁbrotic coronary lesions that cannot be crossed by
a balloon or adequately dilated before stenting. There is little infor-
mation available on procedural, in-hospital, and long term outcome of
provisional RA as compared to a planned rotablation strategy for
complex calciﬁed coronary lesions.
METHODS We performed a retrospective cohort study of all consecutive
patients treated with RA for complex calciﬁed coronary lesions at our
institution between November 2002 and February 2014. Clinical follow-up
was obtained at 1 year by either clinic visit or telephone interview.
RESULTS During this time interval we identiﬁed a total of 512 patients
treated for 559 coronary lesions. 204 patients (39.8%) with 221 lesions
and 308 patients (60.2%) with 338 lesions were treatedwith provisional
and planned RA respectively. Overall, 380 patients (74.2%) weremales,
34.5% had diabetes mellitus and 7.2% had severe chronic renal failure.
A history of myocardial infarction was documented in 18.1% of the
provisional RA population and 27.9% of the elective RA group (p¼0.03).
Other baseline clinical characteristics were similar. Provisional RA
group had signiﬁcantly less lesions located in LAD (41.2% vs 57.1%.
p¼0.002) or involving a bifurcation (28.5% vs 41.1%, p¼0.002), but had
more chronic total occlusions (12.7% vs 2.4%, p<0.001) and more type
B2/C lesions (89.6% vs 80.8%, p¼0.005). DES were implanted in 84.2%
and 87.6% of lesions in the provisional and planned RA groups,
respectively. Coronary dissections occurred more frequently in the
provisional RA group (8.6% vs 4.4%, p¼0.04), and themean procedural
duration and median ﬂuoroscopy time were also longer in that group
(111 50min vs 76 35min, p<0.001 and 32min IQR 21-51 vs 18min IQR
14-28, p<0.001). Angiographic success (deﬁned as residual stenosis <
30%) was lower in the provisional RA group (93.7% vs 97.6%, p¼0.02).
In-hospital death occurred in 6 patients (2.9%) in the provisional RA
group and in 4 patients (1.3%) in the elective RA group (p¼0.21). In-
hospital major adverse cardiac events (MACE) deﬁned as death, MI and
target vessel revascularization (TVR) were signiﬁcantly higher in the
provisional RA group (10.3% vs 5.5%, p¼0.04). At one year follow-up
(available for 94.8% of patients), there was no statistically signiﬁcant
difference in the rates of MACE (18.3% for provisional RA vs. 18.6%
p¼0.52), death (6.5% vs 5.9% p¼0.51), spontaneous MI (1.3% vs 2.7%,
p¼0.29) and TVR (11.3% vs 11.4%, p¼0.52) between the two groups.
CONCLUSIONS In a comparison of provisional and planned RA in a
large cohort of patients treated for complex calciﬁed coronary lesions,
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5 B163improved angiographic success, shortened procedural time and a
reduction of in-hospital events can be obtained with a strategy of
planned RA for selected lesions. However, this strategy does not affect
clinical outcomes at one year.
CATEGORIES CORONARY: Artherectomy (excluding thrombectomy)
KEYWORDS Bailout, Percutaneous coronary intervention, Rotational
atherectomy
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Trial name or ﬁrst
Author
Years
of enrollment Year of publication Design of the trial Inclusion criteria
E
MASS II 1997 – 2001 2004 Single-center RCT Angiographically documented
proximal multivessel disease
(>70% stenosis) and
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(positive stress testing or
stable angina CCS II-III)
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Requir
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FAME 2 2010 - 2012 2012 Multicenter RCT Stable CAD or
angina pectoris CCS class 4
subsequently stabilized
medically (minimum 7 days);
or atypical or no chest pain
but documented ischemia on
non-invasive testing;
plus
At least one stenosis 50% in
at least one major native
coronary artery ( 2.5mm)
and supplying viable
myocardium and
eligible for PCI and
FFR value <80%
Ag
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LMA
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Abbreviations: ACE-I ¼ angiotensin converting enzyme inhibitors; ACS ¼ acute coronary syndrome; AHA ¼ Ame
artery bypass grafting; CAD ¼ coronary artery disease; CCB ¼ calcium channel blockers; CCS ¼ Canadian cardiac s
left main artery; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart Association; OMT ¼ optical m
intervention; STEMI ¼ ST elevation myocardial infarction.Orsola-Malpighi, Bologna, Italy; 9U.O. Cardiologia, University of
Bologna, Bologna, AK
BACKGROUND Stroke is a rare but serious adverse event associated to
PCI. However, the relative risk of stroke between stable patients un-
dergoing a direct PCI strategy and those undergoing OMT has not been
established yet.
METHODS We performed a meta-analysis of 6 contemporary ran-
domized control trials in which 5673 patients with SCAD were ran-
domized to initial PCI or OMT. Only trials with stent utilization more
than 50% were included. Study endpoint was the rate of stroke during
follow up.
RESULTS Mean age of patients ranged from 60 to 65 years and stent
utilization ranged from 72% to 100%. Rate of stroke was 2.0% at a
weighted mean follow up of 55.3 months. On pooled analysis, the risk
of stroke was similar between patients undergoing a PCI plus OMT and
those receiving only OMT (2.2% vs. 1.8%, OR on ﬁxed effect ¼ 1.24 95%
CI: 0.85-1.79). There was no heterogeneity among the studies (I2 ¼
0.0%, P ¼ 0.15). On sensitivity analysis after removing each individual
study the pooled effect estimate remains unchanged.xclusion
criteria Primary endpoint Number of patients
Deﬁnition
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rican Heart Association; ARB ¼ angiotensin receptor blockers; CA ¼ coronary angiography; CABG ¼ coronary
ociety; DES ¼ drug eluting stent, FFR ¼ fractional ﬂow reserve; LAD ¼ left anterior descendent artery; LMA ¼
edical therapy; RCT ¼ randomized controlled trial; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary
